In 2019 Synchron was two years into a $10 million series A when they announced their first human implant, which included a statement by founder and CEO Thomas Oxley:

“This industry is going to unlock the brain’s computational power in ways that are hard to imagine now. This is just the beginning.”

Last week the company announced a $200 Series D to advance their pivotal clinical trial and expand to San Diego, where they are developing their next-generation brain-computer interface system.

I spoke with Oxley to learn more about what’s next for Synchron and discuss BCI past, present, and future.

Memory Lane

Before looking forward, let’s catch up from 2019 to the present:

In 2020 the FDA granted Synchron Breakthrough Designation for their Stentrode. Khosla Ventures led their $40m Serie

See Full Page